We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes.
- Authors
Bock, A. M.; Mwangi, R.; Wang, Y.; Khurana, A.; Maurer, M. J.; Ayers, A.; Kahl, B.; Martin, P.; Cohen, J.; Casulo, C.; Lossos, I.; Farooq, U.; Ayyappan, S.; Reicks, T.; Habermann, T. M.; Flowers, C. R.; Cerhan, J. R.; Nastoupil, L. J.; Nowakowski, G. S.
- Abstract
Defining Primary Refractory Diffuse Large B-cell Lymphoma (DLBCL) Based on Survival Outcomes B Background: b DLBCL that fails to achieve a complete response (CR) or relapses early after standard immunochemotherapy (IC, e.g., R-CHOP or similar) is referred to as primary refractory DLBCL (prDLBCL) and has a poor prognosis. Patients with PD had significantly lower CR/PR rates (19.6%/19.6%) to second line therapy compared to patients with EOT PR (32.1%/30.4%) or early relapse (50.6%/19.1%)( I P i < 0.001).
- Subjects
DIFFUSE large B-cell lymphomas; SURVIVAL rate
- Publication
Hematological Oncology, 2023, Vol 41, p430
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_317